Clinical

Key recommendations and recent updates in the latest version of NCCN guidelines for DLBCL are outlined by Dr Gordon.

Leo Gordon, MD, provides an overview of current treatment strategies currently driven by NCCN guidelines.

Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing Clostridioides difficile infection.

Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.

The researchers found that patients with cancer exposed to immune checkpoint inhibitors have a 1.3% risk of hepatitis B virus reactivation.

Researchers found that EczemaNet2 was more accurate and robust in terms of atopic dermatitis (AD) detection than its predecessor, EczemaNet1.

Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.

Dr Gerds navigates frontline treatments for patients diagnosed with PV.

Dr Gerds reviews the process for updating NCCN guidelines surrounding PV treatment.

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores and patient-reported outcomes (PROs) in patients with multiple myeloma receiving systemic treatment.

The findings of DICTATE-AHF have several implications for cardiologists treating patients with type 2 diabetes, said Zachary Cox, PharmD, professor at Lipscomb University College of Pharmacy.

One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.

Experts examine decision-makers in treatment selection and navigate challenges in organizing multidisciplinary team meetings, from institutional to wider practice perspectives.

Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.

Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.

A panel of experts review what an effective multidisciplinary approach for NSCLC management looks like and subspecialties included in multidisciplinary teams.

New data on dupilumab demonstrate the drug’s potential usefulness in treating type 2 inflammation, a role central to respiratory diseases, including chronic obstructive pulmonary disease (COPD).

Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM).

Psoriasis increases the risk of cutaneous melanoma, according to the findings of a new study.

Lisa Kottschade, RN, CNP, FAPO, a nurse practitioner at Mayo Clinic, discussed immune-related adverse events and biomarkers in relation to melanoma treatment.

The current treatment landscape for CKD patients with preexisting comorbidities is explored.

Dr Nicholas highlights key objectives in developing CKD treatment strategies.

A new study confirmed the validity of a blood test that can diagnose patients with GLUT1 deficiency syndrome, a treatable neurometabolic disease that causes a wide range of neurologic symptoms in children and adults, including seizures.